AP -- GlaxoSmithKline shocked the pharmaceutical industry in 2008 when it dropped $720 million to buy Sirtris Pharmaceuticals, a biotechnology company working on drugs based on resveratrol, a chemical in red wine thought to combat the effects of aging.
